Additional file 1 of 18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study

Romine, Perrin E.; Peterson, Lanell M.; Kurland, Brenda F.; Byrd, Darrin W.; Novakova-Jiresova, Alena; Muzi, Mark; Specht, Jennifer M.; Doot, Robert K.; Link, Jeanne M.; Krohn, Kenneth A.; Kinahan, Paul E.; Mankoff, David A.; Linden, Hannah M.

doi:10.6084/m9.figshare.16417496.v1

13058_2021_1464_MOESM1_ESM.pdf (1016.27 kB)

Additional file 1 of 18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study

journal contribution

posted on 2021-08-24, 03:48 authored by Perrin E. Romine, Lanell M. Peterson, Brenda F. Kurland, Darrin W. Byrd, Alena Novakova-Jiresova, Mark Muzi, Jennifer M. Specht, Robert K. Doot, Jeanne M. Link, Kenneth A. Krohn, Paul E. Kinahan, David A. Mankoff, Hannah M. Linden

Additional file 1. Supplemental Material.

Funding

National Cancer Institute Susan G. Komen Medical Center, University of Pittsburgh

History

Usage metrics

Keywords

FDG-PET FLT-PET Ki-67 ER+ breast cancer Aromatase inhibitors

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 1 of 18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study

Funding

National Cancer Institute Susan G. Komen Medical Center, University of Pittsburgh

History

Usage metrics

Categories

Keywords

Licence

Exports